Skandinaviska Enskilda Banken AB publ increased its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 5.3% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 35,499 shares of the medical equipment provider’s stock after acquiring an additional 1,800 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s holdings in Zimmer Biomet were worth $4,157,000 as of its most recent filing with the SEC.
Other large investors have also added to or reduced their stakes in the company. Bronfman E.L. Rothschild L.P. lifted its stake in shares of Zimmer Biomet by 25.3% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 827 shares of the medical equipment provider’s stock worth $106,000 after acquiring an additional 167 shares in the last quarter. FNY Managed Accounts LLC acquired a new stake in Zimmer Biomet during the third quarter valued at approximately $117,000. BB&T Investment Services Inc. acquired a new stake in Zimmer Biomet during the second quarter valued at approximately $144,000. Sandy Spring Bank raised its stake in Zimmer Biomet by 5.4% during the second quarter. Sandy Spring Bank now owns 1,288 shares of the medical equipment provider’s stock valued at $166,000 after buying an additional 66 shares in the last quarter. Finally, Penserra Capital Management LLC raised its stake in Zimmer Biomet by 13.0% during the second quarter. Penserra Capital Management LLC now owns 1,456 shares of the medical equipment provider’s stock valued at $186,000 after buying an additional 168 shares in the last quarter. Institutional investors and hedge funds own 86.24% of the company’s stock.
Several analysts have issued reports on the company. Oppenheimer set a $137.00 price objective on Zimmer Biomet and gave the company a “buy” rating in a research note on Monday, August 14th. TheStreet cut Zimmer Biomet from a “b-” rating to a “c+” rating in a research note on Friday, November 24th. Gabelli assumed coverage on Zimmer Biomet in a research note on Thursday, August 24th. They set a “buy” rating and a $142.00 price objective on the stock. SunTrust Banks restated a “buy” rating and set a $136.00 price objective on shares of Zimmer Biomet in a research note on Monday, October 2nd. Finally, Morgan Stanley cut their price objective on Zimmer Biomet from $146.00 to $136.00 and set an “overweight” rating on the stock in a research note on Thursday, November 2nd. Four equities research analysts have rated the stock with a sell rating, seven have given a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $133.71.
Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.74 by ($0.02). The company had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.83 billion. Zimmer Biomet had a net margin of 8.36% and a return on equity of 16.29%. The firm’s revenue for the quarter was down .8% compared to the same quarter last year. During the same period last year, the company posted $1.79 earnings per share. sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.03 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Zimmer Biomet Holdings, Inc. (ZBH) Position Lifted by Skandinaviska Enskilda Banken AB publ” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.com-unik.info/2017/12/05/zimmer-biomet-holdings-inc-zbh-position-lifted-by-skandinaviska-enskilda-banken-ab-publ.html.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
What are top analysts saying about Zimmer Biomet Holdings Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Zimmer Biomet Holdings Inc. and related companies.